Literature DB >> 14499584

Interaction of fucoidan with the proteins of the complement classical pathway.

Bérangère Tissot1, Béatrice Montdargent, Lionel Chevolot, Anne Varenne, Stéphanie Descroix, Pierre Gareil, Régis Daniel.   

Abstract

Fucoidan inhibits complement by mechanisms that so far remain to be unraveled, and the objective of this work was to delineate the mode of inhibition by this sulfated polysaccharide. For that purpose, low molecular weight fractions of algal (Ascophyllum nodosum) fucoidan containing the disaccharide unit [-->3)-alpha-L-Fuc(2SO3(-))-(1-->4)-alpha-L-Fuc(2,3diSO3(-))-(1-->](n) have been studied. Gel co-affinity electrophoresis and a new affinity capillary electrophoresis (ACE) method have been implemented to characterize fucoidan-complement protein complexes. Fucoidan binds C1q, likely to its collagen-like region through interactions involving lysine residues, and then prevents the association of the C1r(2)-C1s(2) subunit, required to form the fully active C1. In addition to C1q, fucoidan forms a complex with the protein C4 as observed by ACE. The fucoidan inhibits the first steps of the classical pathway activation that is of relevance in view of the proinflammatory effects of the subsequent products of the cascade. This study shows that a high level of inhibitory activity can be achieved with low molecular weight carbohydrate molecules and that the potential applicability of fucoidan oligosaccharides for therapeutic complement inhibition is worthy of consideration.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14499584     DOI: 10.1016/s1570-9639(03)00230-9

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  12 in total

1.  Fucoidan improves the structural integrity and the molecular stability of β-lactoglobulin.

Authors:  Hyun-Woong Park; Do-Yeong Kim; Weon-Sun Shin
Journal:  Food Sci Biotechnol       Date:  2018-04-11       Impact factor: 2.391

2.  Advances in Studying Glycosaminoglycan-Protein Interactions Using Capillary Electrophoresis.

Authors:  Aiye Liang; Umesh Desai
Journal:  Methods Mol Biol       Date:  2022

3.  Analysis of human C1q by combined bottom-up and top-down mass spectrometry: detailed mapping of post-translational modifications and insights into the C1r/C1s binding sites.

Authors:  Delphine Pflieger; Cédric Przybylski; Florence Gonnet; Jean-Pierre Le Caer; Thomas Lunardi; Gérard J Arlaud; Régis Daniel
Journal:  Mol Cell Proteomics       Date:  2009-12-14       Impact factor: 5.911

Review 4.  Chemical structures and bioactivities of sulfated polysaccharides from marine algae.

Authors:  Guangling Jiao; Guangli Yu; Junzeng Zhang; H Stephen Ewart
Journal:  Mar Drugs       Date:  2011-02-08       Impact factor: 6.085

Review 5.  Therapies from fucoidan; multifunctional marine polymers.

Authors:  Janet Helen Fitton
Journal:  Mar Drugs       Date:  2011-09-30       Impact factor: 6.085

6.  Structural analysis and anti-complement activity of polysaccharides from Kjellmaniella crsaaifolia.

Authors:  Wenjing Zhang; Weihua Jin; Delin Sun; Luyu Zhao; Jing Wang; Delin Duan; Quanbin Zhang
Journal:  Mar Drugs       Date:  2015-03-16       Impact factor: 5.118

7.  Regulation of Complement and Contact System Activation via C1 Inhibitor Potentiation and Factor XIIa Activity Modulation by Sulfated Glycans - Structure-Activity Relationships.

Authors:  Ann-Kathrin Schoenfeld; Eric Lahrsen; Susanne Alban
Journal:  PLoS One       Date:  2016-10-26       Impact factor: 3.240

Review 8.  Complement activation and inhibition in wound healing.

Authors:  Gwendolyn Cazander; Gerrolt N Jukema; Peter H Nibbering
Journal:  Clin Dev Immunol       Date:  2012-12-30

9.  Fucoidan reduces secretion and expression of vascular endothelial growth factor in the retinal pigment epithelium and reduces angiogenesis in vitro.

Authors:  Michaela Dithmer; Sabine Fuchs; Yang Shi; Harald Schmidt; Elisabeth Richert; Johann Roider; Alexa Klettner
Journal:  PLoS One       Date:  2014-02-18       Impact factor: 3.240

Review 10.  Fucoidan as a Potential Therapeutic for Major Blinding Diseases--A Hypothesis.

Authors:  Alexa Klettner
Journal:  Mar Drugs       Date:  2016-02-03       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.